Faculty profile

Dongsheng Tu

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Dongsheng Tu

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
1 publication in the last five years, latest in 2024.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,956

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Clinical Trial Gastroesophageal Cancer Her 2 Positive

Latest papers

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.
The New England journal of medicine · 2024
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years
Journal of Clinical Oncology · 2018
Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial.
Pain · 2016

All 23 publications

Latest funding

Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE trial
CIHR · 2026 · Co-investigator
$1,575,898
Hypofractionated Alternative Radiation with MOdulation of Neoadjuvant/perioperative immunotherapY in Sarcoma (HARMONY)
CIHR · 2025 · Co-investigator
$1,407,600
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial
CIHR · 2022 · Co-investigator
$761,175

All 8 grants and awards

23 publications.

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.

Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE, CX.5 SHAPE investigators, CX.5 SHAPE Investigators

The New England journal of medicine2024

DOI: 10.1056/nejmoa2308900 PMID: 38416430

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K

Journal of Clinical Oncology201820 citations

DOI: 10.1200/jco.2017.75.7500

Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial.

Gilron I, Chaparro LE, Tu D, Holden RR, Milev R, Towheed T, DuMerton-Shore D, Walker S

Pain2016

DOI: 10.1097/j.pain.0000000000000558 PMID: 26982602

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Gelmon K, Rubin S, Sturtz K, Whelan K, Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J

New England Journal of Medicine2016635 citations

DOI: 10.1056/nejmoa1604700

Phase II study of PX-866 in recurrent glioblastoma.

Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP

Neuro-oncology2015

DOI: 10.1093/neuonc/nou365 PMID: 25605819

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

Cheang MCU, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez‐Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz‐Borrego M

Oncologist2015184 citationsOpen Access

DOI: 10.1634/theoncologist.2014-0372 PMID: W2168507982

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2014

DOI: 10.1200/jco.2013.51.2483 PMID: 24711552

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.

Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM

Cancer2014

DOI: 10.1002/cncr.28414 PMID: 24166148

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ, NCIC Clinical Trials Group, Australasian Gastrointestinal Trials Group

Cancer2014

DOI: 10.1002/cncr.28410 PMID: 24127364

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2013

DOI: 10.1200/jco.2012.46.0543 PMID: 23690424

Something wrong or missing on this profile? Suggest a correction

Dongsheng Tu

Research

Latest papers

Latest funding

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years

Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Phase II study of PX-866 in recurrent glioblastoma.

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Frequent collaborators

Mark Norman Levine

Neesha Dhani

William Evans

Timothy Whelan

Harriet Richardson

Lori Brotto

Nicole Mittmann

Lori Brotto

Steven Gallinger

Rita Kandel

James Wright

Ian Gilron

Michael Brundage

Sarah Ferguson

Ian Gilron

Simron Singh

Roumen Milev

Richard Tozer

James Wright

Lori Brotto